Tissue detection of biomolecular predictors in breast cancer

References

• Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res.6, 109–118 (2004).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Baselga J, Milesc D. Molecular approach to breast cancer treatment. Sem. Oncol.31, 6–13 (2004).
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Ravdin P, Hayes DF et al. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol.19(6), 1865–1878 (2001).
   PubMed Web of Science ®Google Scholar
• Molina R, Barak V, van Dalen A et al. Tumor markers in breast cancer – European Group on Tumor Markers recommendations. Tumour Biol.26(6), 281–293 (2005).
   PubMed Web of Science ®Google Scholar
• Ross JS, Schenkein DP, Pietrusko R et al. Targeted therapies for cancer 2004. Am. J. Clin. Pathol.122(4), 598–609 (2004).
   PubMed Web of Science ®Google Scholar
• Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene23(38), 6471–6476 (2004).
   PubMed Web of Science ®Google Scholar
• Dunning AM, Healey CS, Pharoah PD et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev.8(10), 843–854 (1999).
   PubMed Web of Science ®Google Scholar
• Onay VU, Briollais L, Knight JA et al. SNP–SNP interactions in breast cancer susceptibility. BMC Cancer6(1), 114 (2006).
   PubMedGoogle Scholar
• Kristensen VN, Edvardsen H, Tsalenko A et al. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc. Natl Acad. Sci. USA103(20), 7735–7740 (2006).
   PubMed Web of Science ®Google Scholar
• Cebrian A, Pharoah PD, Ahmed S et al. Genetic variants in epigenetic genes and breast cancer risk. CarcinogenesisDOI:10.1093/carcin/bgi375 (2006) (Epub ahead of print).
   PubMedGoogle Scholar
• Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene25(11), 1679–1691 (2006).
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Riener EK, Hefler LA et al. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil. Steril.82(1), 132–137 (2004).
   PubMed Web of Science ®Google Scholar
• Adjei AA, Thomae BA, Prondzinski JL et al. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br. J. Pharmacol.139(8), 1373–1382 (2003).
   PubMed Web of Science ®Google Scholar
• Han W, Kang D, Park IA et al. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin. Cancer Res.10, 124–130 (2004).
   PubMed Web of Science ®Google Scholar
• Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J.6(1), 16–21 (2006).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer12(2), 73–85 (2005).
   PubMedGoogle Scholar
• Barrett-Lee PJ. Growth factor signaling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy. Endocr. Relat. Cancer12(Suppl. 1), S125–S133 (2005).
   PubMedGoogle Scholar
• Emmert-Buck MR, Strausberg RL, Krizman DB et al. Molecular profiling of clinical tissues specimens: feasibility and applications. J. Mol. Diagn.2, 60–66 (2000).
   PubMed Web of Science ®Google Scholar
• Gillespie JW, Best CJ, Bichsel VE et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am. J. Pathol.160, 449–457 (2002).
   PubMed Web of Science ®Google Scholar
• Vincek V, Nassiri M, Nadji M et al. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab. Invest.83(10), 1427–1435 (2003).
   PubMed Web of Science ®Google Scholar
• Morales AR, Nassiri M, Kanhoush R et al. Experience with an automated microwave-assisted rapid tissue processing method: validation of histologic quality and impact on the timeliness of diagnostic surgical pathology. Am. J. Clin. Pathol.121(4), 528–536 (2004).
   PubMed Web of Science ®Google Scholar
• Nadji M, Nassiri M, Vincek V et al. Immunohistochemistry of tissue prepared by a molecular-friendly fixation and processing system. Appl. Immunohistochem. Mol. Morph.13, 277–282 (2005).
   Web of Science ®Google Scholar
• Nadji M. Molecular-friendly histopathology: validation of a robust platform. J. Histotechnol.28, 231–234 (2005).
   Web of Science ®Google Scholar
• Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered. Am. J. Clin. Pathol.123(1), 21–27 (2005).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Col N, Winer EP et al. American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J. Clin. Oncol.20(15), 3328–3343 (2002).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA, Bloom KJ et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell. Proteomics3(4), 379–398 (2004).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17, 2639–2648 (1999).
   PubMed Web of Science ®Google Scholar
• Ocana A, Cruz JJ, Pandiella A. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am. J. Clin. Oncol.29(1), 90–95 (2006).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20, 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Trihia H, Murray S, Price K et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors – a surrogate marker? Cancer97(5), 1321–1331 (2003).
   PubMed Web of Science ®Google Scholar
• Moriya T, Kasajima A, Ishida K et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med. Mol. Morphol.39(1), 8–13 (2006).
   PubMed Web of Science ®Google Scholar
• Rakha EA, Putti TC, Abd El-Rehim DM et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol.208(4), 495–506 (2006).
   PubMed Web of Science ®Google Scholar
• Arpino G, Ciocca DR, Weiss H et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase II α for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat.92(1), 69–75 (2005).
   PubMed Web of Science ®Google Scholar
• Uhlen M, Ponten F. Antibody-based proteomics for human tissue profiling. Mol. Cell. Proteomics.4(4), 384–393 (2005).
   PubMed Web of Science ®Google Scholar
• Hanna WM, Kwok K. Chromogenic in situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod. Pathol.19(4), 481–487 (2006).
   PubMed Web of Science ®Google Scholar
• Bilous M, Morey A, Armes J et al. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology38(2), 120–124 (2006).
   PubMed Web of Science ®Google Scholar
• Di Leo A, Isola J. Topoisomerase II α as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin. Breast Cancer4(3), 179–186 (2003).
   PubMedGoogle Scholar
• Lan C, Liu JM, Liu TW et al. Erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am. J. Clin. Pathol.124(1), 97–102 (2005).
   PubMed Web of Science ®Google Scholar
• Olsen KE, Knudsen H, Rasmussen BB et al. Danish Breast Cancer Co-operative Group. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol.43(1), 35–42 (2004).
   PubMed Web of Science ®Google Scholar
• Liotta L, Petricoin E. Molecular profiling of human cancer. Nat. Rev. Genet.1, 48–56 (2000).
   PubMed Web of Science ®Google Scholar
• Luzzi V, Mahadevappa M, Raja R et al. Accurate and reproducible gene expression profiles from laser capture microdissection, transcript amplification, and high density oligonucleotide microarray analysis. J. Mol. Diag.5(1), 9–14 (2003).
   PubMed Web of Science ®Google Scholar
• Banks RE, Dunn MJ, Forbes MA et al. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis – preliminary findings. Electrophoresis20(4–5), 689–700 (1999).
   PubMed Web of Science ®Google Scholar
• Albertson DG. Profiling breast cancer by array CGH. Breast Cancer Res. Treat.78, 289–298 (2003).
   PubMed Web of Science ®Google Scholar
• Somiari C, Shriver J, He K et al. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. Cancer Genet. Cytogenet.155(2), 108–118 (2004).
   PubMedGoogle Scholar
• Pollack JR, Sorlie T, Perou et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl Acad. Sci.99(20), 12963–12968 (2002).
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Ashworth A. Microarray and histopathological analysis of tumors: the future and the past? Nat. Rev. Cancer1, 151–157 (2001).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci.98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene24(29), 4660–4671 (2005).
   PubMed Web of Science ®Google Scholar
• Adeyinka A, Emberley E, Niu Y et al. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin. Cancer Res.8, 3788–3795 (2002).
   PubMed Web of Science ®Google Scholar
• Ma X, Salunga R, Tuggle JT et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA100, 5974–5979 (2003).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Cronin M, Pho M, Dutta D et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol.164(1), 35–42 (2004).
   PubMed Web of Science ®Google Scholar
• Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol.23(29), 7265–7277 (2005).
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, McLean KC, Paweletz CP et al. New approaches to proteomic analysis of breast cancer. Proteomics1, 1205–1215 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke CH, Buckley JA, Fung ET. SELDI-TOF-MS proteomics of breast cancer. Clin. Chem. Lab. Med.43(12), 1314–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Journet A, Ferro M. The potentials of MS-based subproteomic approaches in medical science: the case of lysosomes and breast cancer. Mass Spectrom. Rev.23(6), 393–442 (2004).
   PubMed Web of Science ®Google Scholar
• Ge Y, Rajkumar L, Raphael C et al. Multiplexed fluorescence detection of phosphorylation, glycosylation, and total protein in the proteomic analysis of breast cancer refractoriness. Proteomics4, 3464–3467 (2004).
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Sgroi DC, Krutzsch et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res.62(22), 6740–6749 (2002).
   PubMed Web of Science ®Google Scholar
• Somiari RI, SullivanR, Russell S. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics3, 1863–1873 (2003).
   PubMed Web of Science ®Google Scholar
• Traub F, Jost M, Hess R et al. Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab. Invest.86(3), 246–253 (2006).
   PubMed Web of Science ®Google Scholar
• Tammen H, Kreipe H, Hess R et al. Expression profiling of breast cancer cells by differential peptide display. Breast Cancer Res. Treat.79(1), 83–93 (2003).
   PubMed Web of Science ®Google Scholar
• Celis JE, Gromova I, Gromov P et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett.580(12), 2935–2944 (2006).
   PubMed Web of Science ®Google Scholar
• Bisca A, D’Ambrosio C, Scaloni A et al. Proteomic evaluation of core biopsy specimens from breast lesions. Cancer Lett.204(1), 79–86 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz SA, Reyzer ML, Caprioli RM. Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. J. Mass Spectrom.38, 699–708 (2003).
   PubMed Web of Science ®Google Scholar
• Chaurand P, Sanders ME, Jensen RA et al. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am. J. Pathol.165(4), 1057–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Petricoin EE, Paweletz CP, Liotta LA. Clinical applications of proteomics: proteomic pattern diagnostics. J. Mammary Gland Biol. Neoplasia7, 433–440 (2002).
   PubMed Web of Science ®Google Scholar
• Khan SA. The role of ductal lavage in the management of women at high risk for breast carcinoma. Curr. Treat. Options Oncol.5, 145–151 (2004).
   PubMedGoogle Scholar
• Paweletz CP, Trock B, Pennanen M et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers17, 301–307 (2001).
   PubMed Web of Science ®Google Scholar
• Fowler LJ, Lovell MO, Izbicka E. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF. Mod. Pathol.17, 1012–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Nadji M, Fresno M, Nassiri M et al. Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum. Pathol.27(9), 890–895 (1996).
   PubMed Web of Science ®Google Scholar
• de Witte JH, Sweep CG, Klijn JG et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br. J. Cancer79, 1190–1198 (1999).
   PubMed Web of Science ®Google Scholar
• Hudelist G, Singer CF, Pischinger KI et al. Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics6(6), 1989–2002 (2006).
   PubMed Web of Science ®Google Scholar
• Celis JE, Gromov P, Gromova I et al. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol. Cell. Proteomics2(6), 369–377 (2003).
   PubMed Web of Science ®Google Scholar